During the past decade, Medizinische Hochschule Hannover; Klinik für Gastroenterologie, Hepatologie und Endokrinologie conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 7 clinical trials were completed, i.e. on average, 58.3% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 5 clinical trials were completed. i.e. 125% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Medizinische Hochschule Hannover; Klinik für Gastroenterologie, Hepatologie und Endokrinologie" #1 sponsor was "Hoffmann-La Roche" with 7 trials, followed by "AIO-Studien-gGmbH" with 3 trials sponsored, "Gilead Sciences" with 1 trials sponsored, "HepNet Study House, German Liverfoundation" with 1 trials sponsored and "Hepatera Ltd." with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Medizinische Hochschule Hannover; Klinik für Gastroenterologie, Hepatologie und Endokrinologie" #1 collaborator was "AstraZeneca" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Data Matrix Solutions" with 1 trials as a collaborator, "Deutsches Krebsforschungszentrum (DKFZ)" with 1 trials as a collaborator and "Gilead Sciences" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Medizinische Hochschule Hannover; Klinik für Gastroenterologie, Hepatologie und Endokrinologie" are "Cholangiocarcinoma Non-resectable" (2 trials), "Hepatitis B, Chronic" (2 trials), "Ulcerative Colitis" (2 trials), "Acute Hepatitis C" (1 trials) and "Carcinoma, Hepatocellular" (1 trials). Many other conditions were trialed in "Medizinische Hochschule Hannover; Klinik für Gastroenterologie, Hepatologie und Endokrinologie" in a lesser frequency.

Most popular intervention types in "Medizinische Hochschule Hannover; Klinik für Gastroenterologie, Hepatologie und Endokrinologie" are "Drug" (13 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Etrolizumab" (2 trials), "Gemcitabine" (2 trials), "Placebo" (2 trials), "5-FU" (1 trials) and "5-fluorouracil" (1 trials). Other intervention names were less common.

The vast majority of trials in "Medizinische Hochschule Hannover; Klinik für Gastroenterologie, Hepatologie und Endokrinologie" are 16 trials for "All" genders.

Currently, there are NaN active trials in "Medizinische Hochschule Hannover; Klinik für Gastroenterologie, Hepatologie und Endokrinologie". 1 are not yet recruiting, 2 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Medizinische Hochschule Hannover; Klinik für Gastroenterologie, Hepatologie und Endokrinologie, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Medizinische Hochschule Hannover; Klinik für Gastroenterologie, Hepatologie und Endokrinologie, 0 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".